D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $91.06
    +0.24 (+0.26%)

    Market Cap: $34.27B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +48.87%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.67
    Range$0.62 - $0.72
    21 analysts
    EPS RevisionsNo revisions (7d)
    7
    9
    30d
    EPS Estimate Drift
    90d ago$0.67+0.0%
    60d ago$0.67+0.4%
    30d ago$0.67+0.3%
    7d ago$0.67+0.0%
    Current$0.67
    Revenue Consensus
    $1.3B
    Range$1.3B - $1.3B
    24 analysts
    Dec 31, 2026
    EPS Consensus$0.91
    Range$0.70 - $1.00
    25 analysts
    Revenue Consensus
    $1.4B
    Range$1.4B - $1.5B
    27 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.91---
    Sep 26EST
    		-$0.67---
    Jun 26
    		$0.70$0.61+14.75%Beat+45.8%
    Mar 26
    		$0.56$0.47+19.15%Beat+75.0%
    Dec 25
    		$0.68$0.65+4.62%Beat+51.1%
    Sep 25
    		$0.61$0.57+7.02%Beat+35.6%
    Jun 25
    		$0.48$0.44+9.09%Beat+11.6%
    Mar 25
    		$0.32$0.33-3.03%Miss+0.0%
    Dec 24
    		$0.45$0.50-10.00%Miss-10.0%
    Sep 24
    		$0.45$0.43+4.65%Beat-10.0%
    Jun 24
    		$0.43$0.39+10.26%Beat+26.5%
    Mar 24
    		$0.32$0.27+18.52%Beat+88.2%
    Dec 23
    		$0.50$0.43+16.28%Beat+47.1%
    Sep 23
    		$0.50$0.33+51.52%Beat+78.6%
    Jun 23
    		$0.34$0.23+47.83%Beat+100.0%
    Mar 23
    		$0.17$0.15+13.33%Beat+112.5%
    Dec 22
    		$0.34$0.28+21.43%Beat+100.0%
    Sep 22
    		$0.28$0.24+16.67%Beat+27.3%
    Jun 22
    		$0.17$0.19-10.53%Miss-10.5%
    Mar 22
    		$0.08$0.13-38.46%Miss+0.0%
    Dec 21
    		$0.17$0.21-19.05%Miss-26.1%
    Sep 21
    		$0.22$0.16+37.50%Beat-8.3%
    Jun 21
    		$0.19$0.11+72.73%Beat-5.0%
    Mar 21
    		$0.08$0.07+14.29%Beat-27.3%
    Dec 20
    		$0.23$0.23+0.00%Beat-20.7%
    Sep 20
    		$0.24$0.16+50.00%Beat+50.0%
    Jun 20
    		$0.20$0.09+122.22%Beat+900.0%
    Mar 20
    		$0.11$0.04+175.00%Beat+1200.0%
    Dec 19
    		$0.29$0.18+61.11%Beat+107.1%
    Sep 19
    		$0.16$0.05+220.00%Beat+300.0%
    Jun 19
    		$0.02$0.01+100.00%Beat+200.0%
    Mar 19
    		$-0.01N/A+75.00%Beat+87.5%
    Dec 18
    		$0.14$0.04+250.00%Beat+366.7%
    Sep 18
    		$0.04$-0.02+300.00%Beat+500.0%
    Jun 18
    		$-0.02$-0.04+50.00%Beat+50.0%
    Mar 18
    		$-0.08$-0.09+11.11%Beat+33.3%
    Dec 17
    		$0.03$0.01+200.00%Beat+250.0%
    Sep 17
    		$-0.01N/A+75.00%Beat+80.0%
    Jun 17
    		$-0.04$-0.06+33.33%Beat-
    Mar 17
    		$-0.12$-0.12+0.00%Beat-
    Dec 16
    		$-0.02$-0.02+0.00%Beat-
    Sep 16
    		$-0.05$-0.03-66.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio35.71EV/EBITDA21.26x
    Price/FCF24.77xFCF Yield4.04%
    Profitability
    Profit Margin20.10%Operating Margin24.30%
    ROE38.50%ROIC25.87%
    Financial Health
    Debt/Equity0.47xInterest CoverageN/A
    Current Ratio1.73xQuick Ratio1.43x
    Trading Statistics
    Beta1.41Avg Volume4.92M
    52-Week High$92.5952-Week Low$54.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$90.24
    SMA 20$88.89
    SMA 50$79.60
    SMA 200$70.29
    EMA 10$89.87
    EMA 20$87.80
    EMA 50$81.88
    EMA 200$73.93

    MACD

    Line: 3.13Signal: 3.58Hist: -0.45

    ADX

    ADX: 30.2+DI: 28.6-DI: 17.1

    Aroon & PSAR

    Aroon Up80.0
    Aroon DownN/A
    PSAR$91.94

    Bollinger Bands

    Upper Band$94.23
    Lower Band$83.54
    %B Position1203%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    64.0

    Momentum Oscillators

    Stoch %K65.7
    Stoch %D64.6
    Williams %R-30.1
    ROC (10d)2.6%
    Momentum2.30
    CCI (20d)57.5
    MFI (14d)65.0

    Volatility Measures

    ATR (14d)$2.59(2.8%)
    StdDev (20d)2.67
    Hist Vol30.0%(Moderate)

    Volume Flow

    VWAP$90.44
    OBV70.5M
    AD Line2.7M
    CMF (20d)0.099

    Volume Metrics

    Avg Vol (20d)4.7M
    Vol Ratio0.6x
    VWMA (20d)$88.69

    Pivot Points

    R3$93.51
    R2$92.18
    R1$91.50
    Pivot Point$90.16
    S1$89.48
    S2$88.15
    S3$87.47

    Advanced Oscillators

    TSI28.78
    Ultimate Osc61.8
    KST176.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.31B$1.19B$1.26B$1.21B$1.16B$1.04B$1.11B$994.20M$1.00B$921.00M$1.03B$975.00M
    Cost of Revenue$478.40M$441.60M$466.90M$477.90M$468.30M$447.00M$457.70M$400.40M$377.60M$359.10M$377.90M$351.70M
    Gross Profit$830.00M$750.30M$792.70M$731.40M$688.80M$589.00M$655.80M$593.80M$626.70M$561.90M$656.60M$623.30M
    Operating Expenses$511.70M$495.00M$469.70M$488.90M$476.20M$455.30M$466.90M$441.80M$468.70M$460.80M$439.70M$417.80M
    R&D$153.00M$145.30M$148.20M$157.50M$148.20M$145.20M$139.50M$135.40M$136.00M$141.50M$136.10M$131.40M
    SG&A$358.70M$349.70M$321.50M$331.40M$328.00M$310.10M$327.40M$306.40M$332.70M$319.30M$303.60M$286.40M
    Operating Income$318.30M$255.30M$323.00M$242.50M$212.60M$133.70M$188.90M$152.00M$158.00M$101.10M$216.90M$205.50M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$800,000$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$317.50M$269.50M$340.70M$352.30M$241.10M$154.30M$211.30M$177.40M$187.80M$132.50M$246.20M$240.40M
    Income Tax Expense$68.40M$70.00M$73.40M$68.50M$61.30M$48.90M$59.60M$42.80M$44.30M$-13,900,000$-10,100,000$119.70M
    Net Income$249.10M$199.50M$267.30M$283.80M$179.80M$105.40M$151.70M$134.60M$143.50M$146.40M$256.30M$120.70M
    EBITDA$385.70M$336.60M$405.90M$415.90M$304.10M$214.30M$269.10M$232.70M$239.90M$185.00M$298.70M$288.60M
    EBIT$317.50M$269.50M$340.70M$352.30M$241.10M$154.30M$211.30M$177.40M$187.80M$132.50M$246.20M$240.40M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DXCM

    News

    Dexcom stock holds steady as CGM growth supports recent earnings

    Dexcom stock is trading in the low $90s, with its valuation supported by double-digit revenue growth from continuous glucose monitoring (CGM) systems. The company has shown significant long-term growth, with a $1,000 investment made in August 2016 now worth nearly $4,000. New guidelines reinforcing CGM data in diabetes management are expected to further drive demand and sustained revenue.

    AD HOC NEWS•8/31/26•
    Bullish

    Trading Systems Reacting to (DXCM) Volatility

    This article from Stock Traders Daily discusses how their AI models are generating trading strategies for Dexcom Inc. (NASDAQ: DXCM) due to conflicting sentiment and volatility. It outlines specific position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for near, mid, and long-term horizons. The report highlights that no resistance levels remain above the current price, suggesting compelling upside potential.

    Stock Traders Daily•8/31/26•
    Neutral

    Dexcom (DXCM) HR chief cashes out 2,565 company shares

    Sadie Stern, EVP Chief People & Culture Officer at Dexcom Inc. (DXCM), sold 2,565 shares of common stock on August 27, 2026, at $88.37 per share. This transaction was conducted under a pre-established Rule 10b5-1 trading plan. Following the sale, Stern directly holds 126,043 shares, including 71,903 unvested restricted stock units.

    Stock Titan•8/29/26•
    Somewhat-Bearish

    Dexcom, Abbott await Medicare coverage expansion for CGMs

    Dexcom and Abbott are anticipating a significant expansion in Medicare coverage for continuous glucose monitors (CGMs) to include people with Type 2 diabetes who do not take insulin. This change could broaden access to their glucose sensors for millions of Americans, potentially reshaping diabetes care. Dexcom CEO Jake Leach and Abbott CEO Robert Ford both view this as a major market opportunity, with Dexcom estimating 25 million non-insulin-using Type 2 diabetics and Abbott expecting 10 million more Medicare recipients to become eligible.

    MedTech Dive•8/29/26•
    Bullish

    DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026

    An officer of DexCom, Sadie Stern, has filed a Rule 144 notice indicating a potential sale of 2,565 shares of common stock on August 27, 2026. The aggregate value of these shares is estimated at $226,669.05, and they originated from restricted stock acquisitions in 2023 and 2024. The sale is planned to occur through Morgan Stanley Smith Barney LLC on NASDAQ.

    Stock Titan•8/28/26•
    Neutral

    Frequently Asked Questions About DXCM

    Does DXCM pay dividends?
    DexCom Inc (DXCM) does not currently pay a regular dividend.
    What is DXCM's P/E ratio?
    DexCom Inc has a price-to-earnings (P/E) ratio of 35.71.
    What is DXCM's market cap?
    DexCom Inc (DXCM) has a market capitalization of $34.27B with a current stock price of $91.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In